Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
About this trial
This is an interventional treatment trial for Non-Hodgkin's Lymphoma
Eligibility Criteria
Key Inclusion Criteria:
Histopathologic confirmation of one of the following cluster of differentiation antigen 20 positive (CD20+) B-cell non-Hodgkin's lymphomas (tissue diagnostic procedures must be performed within 6 months of study entry and with biopsy material available for review):
- follicular lymphoma (NCI CTCAE grade 1 or 2)
- immunoplasmacytoma/immunocytoma (Waldenstrom's macroglobulinemia)
- splenic marginal zone B-cell lymphoma
- extra-nodal marginal zone lymphoma of mucosa-associated lymphoid tumor (MALT) type
- nodal marginal zone B-cell lymphoma
- mantle cell lymphoma
Meets one of the following need-for-treatment criteria (with the exception of mantle cell lymphoma for which treatment is indicated):
presence of at least one of the following B-symptoms:
- fever (>38ºC) of unclear etiology
- night sweats
- weight loss of greater than 10% within the prior 6 months
- large tumor mass (bulky disease)
- presence of lymphoma-related complications, including narrowing of ureters or bile ducts, tumor-related compression of a vital organ, lymphoma-induced pain, cytopenias related to lymphoma/leukemia, splenomegaly, pleural effusions, or ascites
- hyperviscosity syndrome due to monoclonal gammopathy
- CD20+ B cells in lymph node biopsy or other lymphoma pathology specimen.
- No prior treatment (patients on "watch and wait" may enter the study if a recent biopsy [obtained within the last 6 months] is available)
Adequate hematologic function (unless abnormalities related to lymphoma infiltration of the bone marrow or hypersplenism due to lymphoma) as follows:
- hemoglobin of >= 10.0 g/dL
- absolute neutrophil count (ANC) >=1.5*10^9/L
- platelet count >=100*10^9/L
- Bidimensionally measurable disease (field not previously radiated)
- Able to provide written informed consent
- Eastern Cooperative Oncology Group (ECOG) Performance Status <=2
- Estimated life expectancy >=6 months
- Serum creatinine of <=2.0 mg/dL or creatinine clearance >=50 mL/min
- Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤2.5*upper limit of normal (ULN), and alkaline phosphatase and total bilirubin within normal limits
- Left ventricular ejection fraction (LVEF) >= 50% by multiple gated acquisition scan (MUGA) or cardiac echocardiogram (ECHO), prior for any patient to be treated with R-CHOP
- A medically accepted method of contraception to be used by women of childbearing potential (not surgically sterile or at least 12 months naturally postmenopausal)
- Men capable of producing offspring and not surgically sterile must practice abstinence or use a barrier method of birth control.
Key Exclusion Criteria:
- Chronic lymphocytic leukemia, small lymphocytic lymphoma (SLL), or grade 3 follicular lymphoma
- Transformed disease (bone marrow blasts are permitted; however, transformed disease indicating leukemic involvement is not permitted)
- Central nervous system (CNS) lymphomatous involvement or leptomeningeal lymphoma
- Prior radiation for NHL, except for a single course of locally delimited radiation therapy with a radiation field not exceeding 2 adjacent lymph node regions
- Active malignancy, other than NHL, within the past 3 years except for localized prostate cancer treated with hormone therapy, cervical carcinoma in situ, breast cancer in situ, or non-melanoma skin cancer following definitive treatment
- New York Heart Association (NYHA) Class III or IV heart failure, arrhythmias or unstable angina, electrocardiograph (ECG) evidence of active ischemia or active conduction system abnormalities, or myocardial infarction within the last 6 months (prior to study entry, ECG abnormalities at screening must be documented by the investigator as not medically relevant)
- Known human immunodeficiency virus (HIV) positivity
- Active hepatitis B or hepatitis C infection (hepatitis B surface antigen testing required)
- Women who are pregnant or lactating
- Corticosteroids for treatment of lymphoma within 28 days of study entry Chronically administered low-dose corticosteroids (e.g., prednisone ≤20 mg/day) for indications other than lymphoma or lymphoma-related complications are permitted
- Any serious uncontrolled, medical or psychological disorder that would impair the ability of the patient to receive therapy
- Any condition which places the patient at unacceptable risk or confounds the ability of the investigators to interpret study data
- Any other investigational agent within 28 days of study entry
- Known hypersensitivity to bendamustine, mannitol, or other study-related drugs
- Ann Arbor stage I disease.
Sites / Locations
- Teva Investigational Site 165
- Teva Investigational Site 167
- Teva Investigational Site 11
- Teva Investigational Site 21
- Teva Investigational Site 52
- Teva Investigational Site 64
- Teva Investigational Site 40
- Teva Investigational Site 53
- Teva Investigational Site 57
- Teva Investigational Site 15
- Teva Investigational Site 155
- Teva Investigational Site 5
- Teva Investigational Site 70
- Teva Investigational Site 37
- Teva Investigational Site 67
- Teva Investigational Site 58
- Teva Investigational Site 38
- Teva Investigational Site 23
- Teva Investigational Site 65
- Teva Investigational Site 156
- Teva Investigational Site 160
- Teva Investigational Site 68
- Teva Investigational Site 72
- Teva Investigational Site 50
- Teva Investigational Site 73
- Teva Investigational Site 49
- Teva Investigational Site 48
- Teva Investigational Site 9
- Teva Investigational Site 14
- Teva Investigational Site 24
- Teva Investigational Site 152
- Teva Investigational Site 31
- Teva Investigational Site 63
- Teva Investigational Site 47
- Teva Investigational Site 33
- Teva Investigational Site 19
- Teva Investigational Site 43
- Teva Investigational Site 74
- Teva Investigational Site 22
- Teva Investigational Site 4
- Teva Investigational Site 162
- Teva Investigational Site 157
- Teva Investigational Site 29
- Teva Investigational Site 46
- Teva Investigational Site 8
- Teva Investigational Site 10
- Teva Investigational Site 17
- Teva Investigational Site 151
- Teva Investigational Site 39
- Teva Investigational Site 34
- Teva Investigational Site 60
- Teva Investigational Site 28
- Teva Investigational Site 153
- Teva Investigational Site 59
- Teva Investigational Site 44
- Teva Investigational Site 3
- Teva Investigational Site 13
- Teva Investigational Site 7
- Teva Investigational Site 25
- Teva Investigational Site 71
- Teva Investigational Site 56
- Teva Investigational Site 30
- Teva Investigational Site 154
- Teva Investigational Site 158
- Teva Investigational Site 6
- Teva Investigational Site 161
- Teva Investigational Site 159
- Teva Investigational Site 166
- Teva Investigational Site 2
- Teva Investigational Site 18
- Teva Investigational Site 35
- Teva Investigational Site 164
- Teva Investigational Site 54
- Teva Investigational Site 42
- Teva Investigational Site 150
- Teva Investigational Site 163
- Teva Investigational Site 66
- Teva Investigational Site 41
- Teva Investigational Site 62
- Teva Investigational Site 315
- Teva Investigational Site 305
- Teva Investigational Site 317
- Teva Investigational Site 308
- Teva Investigational Site 310
- Teva Investigational Site 311
- Teva Investigational Site 301
- Teva Investigational Site 316
- Teva Investigational Site 304
- Teva Investigational Site 312
- Teva Investigational Site 307
- Teva Investigational Site 318
- Teva Investigational Site 300
- Teva Investigational Site 303
- Teva Investigational Site 314
- Teva Investigational Site 313
- Teva Investigational Site 309
- Teva Investigational Site 503
- Teva Investigational Site 504
- Teva Investigational Site 506
- Teva Investigational Site 505
- Teva Investigational Site 502
- Teva Investigational Site 509
- Teva Investigational Site 507
- Teva Investigational Site 508
- Teva Investigational Site 511
- Teva Investigational Site 500
- Teva Investigational Site 501
- Teva Investigational Site 202
- Teva Investigational Site 206
- Teva Investigational Site 200
- Teva Investigational Site 201
- Teva Investigational Site 203
- Teva Investigational Site 204
- Teva Investigational Site 602
- Teva Investigational Site 603
- Teva Investigational Site 600
- Teva Investigational Site 601
- Teva Investigational Site 401
- Teva Investigational Site 405
- Teva Investigational Site 400
- Teva Investigational Site 402
- Teva Investigational Site 404
- Teva Investigational Site 403
- Teva Investigational Site 700
- Teva Investigational Site 701
- Teva Investigational Site 704
- Teva Investigational Site 702
- Teva Investigational Site 703
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Bendamustine and Rituximab (BR)
R-CHOP/R-CVP
Participants received the investigational bendamustine and rituximab regimen for 6 to 8 28-day cycles: bendamustine 90 mg/m^2 intravenous (IV) on Days 1 and 2; rituximab 375 mg/m^2 IV on Day 1
Participants received the standard regimen (R-CHOP or R-CVP) for 6 to 8 21-days cycles. R-CHOP: rituximab 375 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; doxorubicin 50 mg/m^2 IV Day 1; cyclophosphamide 750 mg/m^2 IV Day 1; prednisone 100 mg oral on Days 1 to 5 R-CVP: rituximab 375 mg/m^2 IV on Day 1; cyclophosphamide 750 mg/m^2 IV on Day 1 or cyclophosphamide 1000 mg/m^2 IV on Day 1; vincristine 1.4 mg/m^2 (up to 2 mg/m^2 maximum dose) IV on Day 1; prednisone 100 mg oral on Days 1 to 5